PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders - Archive ouverte HAL Access content directly
Journal Articles Journal of Inherited Metabolic Disease Year : 2008

PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders

(1) , (1)
1

Abstract

Enzyme defects in the mitochondrial fatty acid oxidation (FAO) are a large family of inherited metabolic disease well characterized clinically and genetically, but for which pharmacological strategies remain limited. It is now well established that regulation of genes involved in mitochondrial FAO is under control of the PPAR (peroxisome proliferator activated receptor) signalling pathway, and this led us to test a possible pharmacological correction of FAO disorders by fibrates and other PPAR activators. This review presents the basic data supporting our initial hypothesis, summarizes the results obtained in cells from patients with CPT II (carnitine palmitoyltransfer-ase II) or VLCAD (very long-chain acyl-CoA dehydro-genase) deficiency, and discusses the perspectives and limits of this approach for therapy of these disorders. Abbreviations CPT II carnitine palmitoyltransferase II FALDH fatty aldehyde dehydrogenase FAO fatty acid oxidation PPAR peroxisome proliferator activated receptor RXR retinoid X receptor VLCAD very long-chain acyl-CoA dehydrogenase
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02896250 , version 1 (10-07-2020)

Identifiers

Cite

F. Djouadi, J. Bastin. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders. Journal of Inherited Metabolic Disease, 2008, 31 (2), pp.217-225. ⟨10.1007/s10545-008-0844-7⟩. ⟨inserm-02896250⟩

Collections

INSERM CNRS
8 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More